Rolapitant for the treatment of chemotherapy-induced nausea and vomiting

Academic Article

Abstract

  • © 2015 Informa UK, Ltd. Chemotherapy-induced nausea and vomiting is a significant clinical issue which affects patients quality of life and treatment decisions. Significant improvements in the control of chemotherapy-induced nausea and vomiting have occurred in the past 15 years with the introduction of new antiemetic agents 5-HT3, receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and olanzapine. Aprepitant was the first NK-1 receptor antagonist introduced (2003) for the prevention of chemotherapy-induced nausea and vomiting in combination with a 5-HT3 receptor antagonist and dexamethasone. A second NK-1 receptor antagonist netupitant was approved for use in October 2014. Phase III clinical trials of an additional NK-1 receptor antagonist rolapitant have been completed, and the data have been submitted for regulatory approval. A description of rolapitant and its role in chemotherapy-induced nausea and vomiting will be presented, along with a comparison of the other neurolinin-1 receptor antagonists aprepitant and netupitant.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Navari RM
  • Start Page

  • 1127
  • End Page

  • 1133
  • Volume

  • 15
  • Issue

  • 10